New mechanism of action of tumour therapy discovered

19.04.2018

In an early study in the USA, an active substance against cancer developed in cooperation with the University of Vienna showed first indications of therapeutic efficacy combined with good tolerability. A team led by Bernhard Keppler from the Faculty of Chemistry has now been able to show that the active substance causes symptoms of immunogenic cell death in cancer cells and could thus play a central role in drug-based cancer therapy. The latest findings on the mechanism of action of the promising KP-1339 (IT-139) were presented at this year's Annual Meeting of the American Association of Cancer Research (AACR), recently held in Chicago.

Press release of the University of Vienna (in German): 19 April 2018: Neuer Wirkmechanismus von Tumortherapeutikum entdeckt
Press release published by Intezyne:13 April 2018: Data Showing that IT-139 Triggers Immunogenic Cell Death (ICD) to Be Presented at AACR 2018 Annual Meeting
Press release, 20 Juli 2017: Intezyne Technologies Granted Orphan Drug Designation for IT-139 in Pancreatic Cancer
Website Intezyne: IT-139

Back